No research matches these filters.
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet
Phase 3 study that can add or remove treatments
Metformin + alpha-lipoic acid
Ongoing • results from the first stage are being reviewed
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Phase 3 study in people • the first-stage decision is still awaited
What to watch next: A decision on which initial treatment groups will continue is expected around October 2026
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet
Phase 2
Metformin • progressive MS
Ongoing, but not accepting new participants
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Phase 2 study in people • results are awaited
What to watch next: Completion of participant follow-up and publication of the results
Emerging treatmentsMyelin repair
Registered study in peopleLooking for participantsNo evidence of benefit in people yet
Phase 2
Metformin • people aged 55–75
Looking for participants • NCT06463743
Practical availability: Study in people — looking for participants does not guarantee access
What kind of evidence exists?: Phase 2 study in people • results are awaited
What to watch next: Results on safety and on changes measured with brain scans and specialised measurements of myelin
Emerging treatmentsMyelin repair
Registered study in peopleLooking for participantsNo evidence of benefit in people yet
Phase 2
Drug acting on the CXCR7/ACKR3 receptors • progressive MS
Looking for participants
Practical availability: Study in people — looking for participants does not guarantee access
What kind of evidence exists?: Phase 2 study in people • results are awaited
What to watch next: At 48 weeks, MRI, electrical nerve tests and biochemical tests will look for possible signs of myelin repair
Emerging treatmentsMyelin repair
Registered study in peopleLooking for participantsNo evidence of benefit in people yet
Phase 1/2
Clemastine • long-term loss of myelin
Looking for participants
Practical availability: Study in people — looking for participants does not guarantee access
What kind of evidence exists?: Phase 1/2 study in people • results are awaited
What to watch next: MRI scans using several measurements will look for possible changes in myelin • estimated completion in 2027
Emerging treatmentsMyelin repair
Registered study in peopleLooking for participantsNo evidence of benefit in people yet
Phase 2
Clemastine • sudden inflammation of the optic nerve
Looking for participants
Practical availability: Study in people — looking for participants does not guarantee access
What kind of evidence exists?: Phase 2 study in people • results are awaited
What to watch next: Electrical testing of the visual pathway and MRI will look for possible signs of myelin repair • estimated completion in 2028
Emerging treatmentsMyelin repair
Registered study in peopleNot accepting participants yetNo evidence of benefit in people yet
Phase 1/2
Clemastine • recent areas of myelin loss
Not yet accepting participants • scheduled start 15 September 2026
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Phase 1/2 study in people • no results yet
What to watch next: The study will begin looking for participants and use MRI scans with several measurements to look for possible myelin repair
Emerging treatmentsMyelin repair
Registered study in peoplePausedNo evidence of benefit in people yet
Phase 1/2
Ifenprodil • possible myelin repair
Temporarily paused in the European CTIS registry
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Phase 1/2 study in people • temporarily paused
What to watch next: Official confirmation that the study has restarted, or another update on its status
Emerging treatmentsMyelin repair
Registered study in peopleLooking for participantsNo evidence of benefit in people yet
Small pilot study of a medical device
Stimulation of the vagus nerve • relapsing-remitting MS
Looking for participants
Practical availability: Study in people — looking for participants does not guarantee access
What kind of evidence exists?: Pilot device study in people • early exploration of possible benefit
What to watch next: Safety and early signs of myelin repair will be assessed after 48 weeks
Emerging treatmentsMyelin repair
Registered study in peopleLooking for participantsNo evidence of benefit in people yet
Phase 2
Testosterone • relapsing-remitting MS
Ongoing • looking for participants
Practical availability: Study in people — looking for participants does not guarantee access
What kind of evidence exists?: Phase 2 study in people • results are awaited
What to watch next: MRI scans will look for possible signs of myelin repair and protection of nerves
Emerging treatmentsMyelin repair
Safety and how the body processes the drugAnnounced or plannedPermission or regulatory step
Phase 1 • initially in healthy volunteers
PTD802, a drug that acts on the GPR17 receptor
Permission has been given for the first study in people
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Study in healthy volunteers • no evidence of benefit in people with MS
What to watch next: Researchers will first assess safety, side effects and how the body processes the drug
Emerging treatmentsMyelin repair
Planned study in peopleAnnounced or plannedPermission or regulatory step
Planned Phase 2 study
Lucid-21-302, a drug that blocks PAD2 • progressive MS
The FDA allowed the research to move forward • no public study registration was found
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Step toward a study in people • no evidence of benefit in people with MS
What to watch next: Public registration of the Phase 2 study, announcement of participating centres and the start of participant enrolment
Emerging treatmentsMyelin repair
Preparing for first human studiesAnnounced or plannedNo evidence of benefit in people yet
Preparing for the first study in people
Low-dose theophylline skin patch
Funding supports improvement of the patch and manufacture to pharmaceutical standards • a study in healthy volunteers is planned
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: No evidence of benefit in people with MS • laboratory findings and patch-development work only
What to watch next: Testing the improved patch, manufacturing it to pharmaceutical standards and running the first safety study in people
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding
Laboratory and animal research
Bavisant, a drug that acts on the histamine H3 receptor
Promising results in human cells and animal models • no registered study in people with MS
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: Tests in human cells and animal models • no evidence of benefit in patients
What to watch next: Further drug development and formal registration of a study in people
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding
Laboratory and animal research aiming toward a future study in people
DITPA, a drug related to thyroid hormone
Active Monash research through 2028 • it has not yet reached a study in people
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: Laboratory and animal findings only • no proven benefit in people with MS
What to watch next: Confirmation in a paper reviewed by independent scientists, checks required by regulators and public registration of a study in people
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding
Improvement work before studies in people
CN045, a small molecule that helps immature cells become myelin-making cells
Promising results in human cells in the laboratory and in mice
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: Laboratory and animal findings only • no proven benefit in people with MS
What to watch next: Improve the molecule, test how the body processes it and check for possible toxicity before selecting a final version for future study
Emerging treatmentsMyelin repair
Preparing for first human studiesLaboratory or animal programmeNo evidence of benefit in people yet
Advanced laboratory development
A fixed-dose combination of two small molecules
A candidate combination was selected because the two molecules together increased myelin repair in experimental models
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: Laboratory and animal findings only • no proven benefit in people with MS
What to watch next: Further development and safety checks before researchers can request permission for a study in people
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmeNo evidence of benefit in people yet
Laboratory and animal research • a development partner is being sought
New small molecules that activate the mGluR5 receptor
Activity was seen in human myelin-making cells and animal models • a patent application is pending
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: Laboratory and animal findings only • no proven benefit in people with MS
What to watch next: Select the best molecule and complete the checks needed before requesting permission for a study in people
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding
Cell therapy in animal models
Transplanting neural stem cells
Early evidence that the idea may work in models of long-term myelin loss
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: Laboratory and animal findings only • no proven benefit in people with MS
What to watch next: Tests of delivery, dose and safety before a study in people can be considered
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding
Cell therapy in animal models
Genetically modified human cells that can make myelin
The cells moved more effectively toward long-term injuries and increased myelin repair in rodents
Practical availability: Laboratory or animal research — not a treatment available to patients
What kind of evidence exists?: Laboratory and animal findings only • no proven benefit in people with MS
What to watch next: Develop a reliable manufacturing process and complete long-term safety checks before a study in people
Emerging treatmentsMyelin repair
Results from peopleCompletedPromising early finding
Phase 2a • completed
Metformin + clemastine
Promising change in the brain's electrical response to vision
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Results in people • a biological sign was seen, but no short-term improvement in disability
What comes next: A full paper reviewed by independent scientists and a larger study to confirm the result
Emerging treatmentsMyelin repair
Results from peopleCompletedNo clear effect found
Phase 2 • completed
Bazedoxifene acetate
The study's main and secondary measures of myelin repair were not reached
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Results in people • no clear benefit was found in the measures of myelin repair
What this means: The drug was generally well tolerated, but it did not show a statistically clear benefit
Emerging treatmentsMyelin repair
Results from peopleTerminated / stoppedDid not show the hoped-for effect
Phase 3 • stopped
Clemastine • an MS-related disorder of eye movement
The study stopped after an early review found it was unlikely to reach its goal
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Phase 3 study in people • stopped after difficulty finding participants and an early review
What this means: The decision was linked to slow enrolment and the early review; by itself, it does not prove conclusively that clemastine is ineffective
Emerging treatmentsMyelin repair
Results from peopleCompletedDid not show the hoped-for effect
Phase 2 • completed
PIPE-307, a drug that blocks the M1 receptor
The study's planned measures did not show the hoped-for benefit
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Results in people • the measures of benefit did not show the expected effect
What this means: It remains uncertain whether the drug will continue to be developed for MS
Emerging treatmentsMyelin repair
Results from peopleCompletedNo evidence of benefit in people yet
Early Phase 1 • completed
Metformin • primary or secondary progressive MS
Completed • results have not yet been published
Practical availability: Research only — not an established treatment
What kind of evidence exists?: Early Phase 1 study in people • public results are awaited
What comes next: Public results on safety and possible benefit from study NCT05349474